Background The incidence of leg edema caused by calcium channel blockers（CCB） is so high, some studies tried combination with angiotension converting enzyme inhibitors（ACEI） or diuretics to overcome this problem.H...Background The incidence of leg edema caused by calcium channel blockers（CCB） is so high, some studies tried combination with angiotension converting enzyme inhibitors（ACEI） or diuretics to overcome this problem.However, there is no comparison about which is better to improve edema at present. Methods This study was designed as a single-center, prospective, randomized, double-blind, parallel-group, clinical trial. 224 hypertensive patients with leg edema after 4 weeks since taking levamlodipine were enrolled, and they were randomly divided into levamlodipine ＋ furosemide（CD） group and levamlodipine ＋ enalapril（CA） group for another 4 weeks. Ankle circumference（AC）, edema score（ES）, blood pressure（BP） and cure rate of leg edema were evaluated. Results Altogether 179 patients（89 in CD group and 90 in CA group） completed the 4-week treatment. After the 4-week therapy with furosemide or enalapril, most subjects were free of edema in either group（96.51% vs.96.67%, P 〉 0.05）. Only 4 in CD group and 3 in CA group had mild edema. Enalapril was more effective than furosemide to reduce AC（10.92 ± 1.84 mm vs. 12.97 ± 2.46 mm, P 〈 0.05）. But for ES, there was no significant difference. And there were no significant differences in antihypertensive effect between them. Uric acid（UA）was increased significantly in CD group（10.70 ± 18.48 μmol/L vs. 0.22 ± 28.13 μmol/L, P 〈 0.05）. Conclusion Enalapril is more effective than furosemide in attenuating lower extremity edema caused by levamlodipine in essential hypertensive population, with equal antihypertensive efficacy and less uric acid increasing.展开更多
Objective:To investigate the effectiveness and efficiency of combining levamlodipine besylate and valsartan in the treatment of hypertension.Methods:This study selected 28 patients with hypertension as observation sub...Objective:To investigate the effectiveness and efficiency of combining levamlodipine besylate and valsartan in the treatment of hypertension.Methods:This study selected 28 patients with hypertension as observation subjects.The treatment duration ranged from January 2020 to June 2023.Using the random number table method,patients were divided into two groups.The control group received treatment with valsartan,while the observation group received a combination of valsartan and levamlodipine besylate.Therapeutic effects and safety were compared between the groups,and changes in the patient’s blood pressure and renal function index levels were assessed.Results:The total clinical effective rate of the observation group was significantly higher than that of the control group(P<0.05).The observation group demonstrated better diastolic blood pressure,systolic blood pressure,and renal function indicators compared to the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combined treatment of levamlodipine besylate and valsartan in patients with hypertension showed significant clinical efficacy and holds broad application value.展开更多
Objective: the main purpose of this article is to observe the application effect of Levamlodipine besylate tablets in the treatment of hypertension patients. Methods: it will be between June 2017 to June 2019 of 50 ca...Objective: the main purpose of this article is to observe the application effect of Levamlodipine besylate tablets in the treatment of hypertension patients. Methods: it will be between June 2017 to June 2019 of 50 cases of hypertensive patients admitted in the hospital for as analysis object, and according to the patient, even on admission to hospital to carry on the grouping, the two were divided into control group and observation group, each group has between 25 patients, control group is used during treatment of los plain radiographs, patients in the observation group received levamlodipine besylate tablets during treatment. The two different treatment methods and the effect of the final treatment were compared and observed. Results: according to the relevant indicators and data of the two groups of patients, the observation group of patients compared with the control group of patients, the observation group of patients with hypertension has been effectively controlled, and the treatment effect is also significantly improved, the difference between the two groups of data results is very obvious. Conclusion: for patients with hypertension in the process of treatment with levamlodipine besylate tablets for the treatment of hypertension, can make patients with hypertension effectively control, so as to help patients improve the level of life and quality.展开更多
The clinical application value of levamlodipine besylate tablets selected by hypertension patients was considered. Methods one hundred and forty patients with hypertension admitted to our internal medicine department ...The clinical application value of levamlodipine besylate tablets selected by hypertension patients was considered. Methods one hundred and forty patients with hypertension admitted to our internal medicine department from June 2020 to June 2021 were selected and divided into two groups according to the blind selection and grouping method, namely, the experimental group and the control group, with 70 patients in each group. Among them, the therapeutic drug selected by the experimental group was levamlodipine besylate tablets, and the therapeutic drug selected by the control group was nifedipine sustained-release tablets. The clinical therapeutic effects of the two groups were statistically compared. Results: in terms of clinical total effective rate, the experimental group and the control group were 97.14% and 77.14% respectively. The difference between the two groups was significant and there was a statistical advantage (P < 0.05). As for the adverse reaction rate, the experimental group and the control group were 4.29% and 8.57% respectively, and there was no significant difference between the two groups with statistical advantage (P > 0.05). Conclusion: for the clinical treatment of hypertension, levo-aminochloride besylate is an effective drug with no serious adverse reactions. It has strong clinical application value.展开更多
Objective: To investigate the effect of Levorotatory Amlodipine on carotid atherosclerosis, inflammatory response and endothelial function in hypertensive patients. Methods: A total of 180 cases of patients with essen...Objective: To investigate the effect of Levorotatory Amlodipine on carotid atherosclerosis, inflammatory response and endothelial function in hypertensive patients. Methods: A total of 180 cases of patients with essential hypertension were randomly divided into control group and observation group. In the control group, life intervention was treated, and the observation group was treated with l-amlodipine in addition to life intervention, and continued treatment for 5 months. The oxidative stress index, inflammatory factor, vascular endothelial function index and β2-microglobulin and PDGF-BB levels were compared before and after treatment. Results: There were no significant differences in the levels of oxidative stress indicators MDA, SOD, inflammatory factors TNF- , hs-CRP, vascular endothelial function markers ET-1, NO,β2-microglobulin and PDGF-BB before treatment. The levels of MDA, TNF-α, hs-CRP, ET-1, β2-microglobulin and PDGF-BB in the two groups were significantly lower than those in the same group before treatment. The levels of SOD and NO were significantly higher than those in the same group. The levels of TNF-α and hs-CRP in the observation group were (26.64±2.79) ng/L and (8.29±3.15) mg/L, respectively, which were significantly lower than those in the control group. The level of ET-1 in the observation group was (50.31±21.72) ng/L significantly lower than that in the control group, and the level of NO was (78.27±16.14)μmol/L was significantly higher than that in the control group. The observation group β2-microglobulin and PDGF-BB were (2.29±0.23) mg/L and (19.06±1.91) ng/mL, which were significantly lower than the control group. Conclusion: L-amlodipine in the treatment of hypertension can effectively reduce the level of oxidative stress, inhibit the release of inflammatory factors and significantly improve vascular endothelial function, which has certain clinical value.展开更多
基金supported by National Natural Science Foundation of China(No.81641058)
文摘Background The incidence of leg edema caused by calcium channel blockers（CCB） is so high, some studies tried combination with angiotension converting enzyme inhibitors（ACEI） or diuretics to overcome this problem.However, there is no comparison about which is better to improve edema at present. Methods This study was designed as a single-center, prospective, randomized, double-blind, parallel-group, clinical trial. 224 hypertensive patients with leg edema after 4 weeks since taking levamlodipine were enrolled, and they were randomly divided into levamlodipine ＋ furosemide（CD） group and levamlodipine ＋ enalapril（CA） group for another 4 weeks. Ankle circumference（AC）, edema score（ES）, blood pressure（BP） and cure rate of leg edema were evaluated. Results Altogether 179 patients（89 in CD group and 90 in CA group） completed the 4-week treatment. After the 4-week therapy with furosemide or enalapril, most subjects were free of edema in either group（96.51% vs.96.67%, P 〉 0.05）. Only 4 in CD group and 3 in CA group had mild edema. Enalapril was more effective than furosemide to reduce AC（10.92 ± 1.84 mm vs. 12.97 ± 2.46 mm, P 〈 0.05）. But for ES, there was no significant difference. And there were no significant differences in antihypertensive effect between them. Uric acid（UA）was increased significantly in CD group（10.70 ± 18.48 μmol/L vs. 0.22 ± 28.13 μmol/L, P 〈 0.05）. Conclusion Enalapril is more effective than furosemide in attenuating lower extremity edema caused by levamlodipine in essential hypertensive population, with equal antihypertensive efficacy and less uric acid increasing.
文摘Objective:To investigate the effectiveness and efficiency of combining levamlodipine besylate and valsartan in the treatment of hypertension.Methods:This study selected 28 patients with hypertension as observation subjects.The treatment duration ranged from January 2020 to June 2023.Using the random number table method,patients were divided into two groups.The control group received treatment with valsartan,while the observation group received a combination of valsartan and levamlodipine besylate.Therapeutic effects and safety were compared between the groups,and changes in the patient’s blood pressure and renal function index levels were assessed.Results:The total clinical effective rate of the observation group was significantly higher than that of the control group(P<0.05).The observation group demonstrated better diastolic blood pressure,systolic blood pressure,and renal function indicators compared to the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combined treatment of levamlodipine besylate and valsartan in patients with hypertension showed significant clinical efficacy and holds broad application value.
文摘Objective: the main purpose of this article is to observe the application effect of Levamlodipine besylate tablets in the treatment of hypertension patients. Methods: it will be between June 2017 to June 2019 of 50 cases of hypertensive patients admitted in the hospital for as analysis object, and according to the patient, even on admission to hospital to carry on the grouping, the two were divided into control group and observation group, each group has between 25 patients, control group is used during treatment of los plain radiographs, patients in the observation group received levamlodipine besylate tablets during treatment. The two different treatment methods and the effect of the final treatment were compared and observed. Results: according to the relevant indicators and data of the two groups of patients, the observation group of patients compared with the control group of patients, the observation group of patients with hypertension has been effectively controlled, and the treatment effect is also significantly improved, the difference between the two groups of data results is very obvious. Conclusion: for patients with hypertension in the process of treatment with levamlodipine besylate tablets for the treatment of hypertension, can make patients with hypertension effectively control, so as to help patients improve the level of life and quality.
文摘The clinical application value of levamlodipine besylate tablets selected by hypertension patients was considered. Methods one hundred and forty patients with hypertension admitted to our internal medicine department from June 2020 to June 2021 were selected and divided into two groups according to the blind selection and grouping method, namely, the experimental group and the control group, with 70 patients in each group. Among them, the therapeutic drug selected by the experimental group was levamlodipine besylate tablets, and the therapeutic drug selected by the control group was nifedipine sustained-release tablets. The clinical therapeutic effects of the two groups were statistically compared. Results: in terms of clinical total effective rate, the experimental group and the control group were 97.14% and 77.14% respectively. The difference between the two groups was significant and there was a statistical advantage (P < 0.05). As for the adverse reaction rate, the experimental group and the control group were 4.29% and 8.57% respectively, and there was no significant difference between the two groups with statistical advantage (P > 0.05). Conclusion: for the clinical treatment of hypertension, levo-aminochloride besylate is an effective drug with no serious adverse reactions. It has strong clinical application value.
文摘Objective: To investigate the effect of Levorotatory Amlodipine on carotid atherosclerosis, inflammatory response and endothelial function in hypertensive patients. Methods: A total of 180 cases of patients with essential hypertension were randomly divided into control group and observation group. In the control group, life intervention was treated, and the observation group was treated with l-amlodipine in addition to life intervention, and continued treatment for 5 months. The oxidative stress index, inflammatory factor, vascular endothelial function index and β2-microglobulin and PDGF-BB levels were compared before and after treatment. Results: There were no significant differences in the levels of oxidative stress indicators MDA, SOD, inflammatory factors TNF- , hs-CRP, vascular endothelial function markers ET-1, NO,β2-microglobulin and PDGF-BB before treatment. The levels of MDA, TNF-α, hs-CRP, ET-1, β2-microglobulin and PDGF-BB in the two groups were significantly lower than those in the same group before treatment. The levels of SOD and NO were significantly higher than those in the same group. The levels of TNF-α and hs-CRP in the observation group were (26.64±2.79) ng/L and (8.29±3.15) mg/L, respectively, which were significantly lower than those in the control group. The level of ET-1 in the observation group was (50.31±21.72) ng/L significantly lower than that in the control group, and the level of NO was (78.27±16.14)μmol/L was significantly higher than that in the control group. The observation group β2-microglobulin and PDGF-BB were (2.29±0.23) mg/L and (19.06±1.91) ng/mL, which were significantly lower than the control group. Conclusion: L-amlodipine in the treatment of hypertension can effectively reduce the level of oxidative stress, inhibit the release of inflammatory factors and significantly improve vascular endothelial function, which has certain clinical value.
